685 results on '"Swigris, Jeffrey J."'
Search Results
2. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants.
3. First ever characterisation of the effects of short telomeres in a Singapore interstitial lung disease cohort
4. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
5. A first look at the reliability, validity and responsiveness of L-PF-35 dyspnea domain scores in fibrotic hypersensitivity pneumonitis
6. Serum antibodies to peptidylarginine deiminase-4 in rheumatoid arthritis associated-interstitial lung disease are associated with decreased lung fibrosis and improved survival
7. Reliability, Validity, and Responsiveness of the DEG, a Three-Item Dyspnea Measure
8. Digital outcome measures in pulmonary clinical trials
9. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency
10. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
11. Deep Learning Classification of Usual Interstitial Pneumonia Predicts Outcomes.
12. Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
13. The Role of Pulmonary Rehabilitation and Supplemental Oxygen Therapy in the Treatment of Patients with Idiopathic Pulmonary Fibrosis
14. IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis
15. The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation
16. Reliability and responsiveness of the D12 and validity of its scores as a measure of dyspnoea severity in patients with rheumatoid arthritis-related interstitial lung disease
17. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience
18. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis
19. Reliability and validity of Chinese version of a tool to assess the quality of life in idiopathic pulmonary fibrosis in patients with interstitial lung disease
20. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis
21. Deep Learning--based Fibrosis Extent on Computed Tomography Predicts Outcome of Fibrosing Interstitial Lung Disease Independent of Visually Assessed Computed Tomography Pattern.
22. Is it time to include oxygen needs as an endpoint in clinical trials in patients with fibrosing interstitial lung disease? If so, how?
23. The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease
24. Looking ahead and behind at supplemental oxygen: A qualitative study of patients with pulmonary fibrosis
25. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety
26. Burden of idiopathic pulmonary fibrosis on patients’ emotional well being and quality of life: a literature review
27. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival
28. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
29. Preface
30. List of Contributors
31. Therapeutic Options for Patients With Idiopathic Pulmonary Fibrosis
32. The Role of Pulmonary Rehabilitation and Supplemental Oxygen Therapy in the Treatment of Patients with Idiopathic Pulmonary Fibrosis
33. Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
34. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives
35. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience
36. Association Between Occupational Exposures and Sarcoidosis: An Analysis From Death Certificates in the United States, 1988-1999
37. Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
38. The Role of Pulmonary Rehabilitation and Supplemental Oxygen Therapy in the Treatment of Patients with Idiopathic Pulmonary Fibrosis
39. Pulmonary Manifestations of Systemic Lupus Erythematosus (SLE)
40. Idiopathic Pulmonary Fibrosis
41. Contributors
42. Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort.
43. Idiopathic pulmonary fibrosis: Epidemiology, natural history and pathophysiology
44. Acute Fibrinous Organizing Pneumonia in a COVID-19 Patient: A Case Report.
45. Idiopathic pulmonary fibrosis
46. A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen
47. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
48. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
49. FEV1 over time in patients with connective tissue disease-related bronchiolitis
50. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.